Results 11 to 20 of about 18,414 (179)

Clinical Evaluation of Drug-Drug Interactions With Aficamten. [PDF]

Clin Transl Sci
ABSTRACT Aficamten is a next‐in‐class small molecule cardiac myosin inhibitor that was recently approved by the United States Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). A comprehensive drug–drug interaction (DDI) evaluation of aficamten was achieved through two phase 1 studies in ...
Maharao N, Xu D, Divanji P, Simkins TJ, Li J, Dumitrescu C, Solanki P, Griffith A, Heitner SB, Kupfer S, German P, Lutz JD.   +11 more
europepmc   +2 more sources

Estudio de las variantes alélicas CYP2C9*2 y CYP2C9*3 en muestras de población mestiza peruana

Biomédica: revista del Instituto Nacional de Salud, 2019
Introducción. El citocromo CYP2C9 metaboliza, aproximadamente, el 15 % de los fármacos prescritos. Su gen presenta alelos cuyas frecuencias difieren entre grupos étnicos y poblaciones. Los alelos CYP2C9*2 y CYP2C9*3 dan cuenta de una enzima con actividad
Ángel Tito Alvarado, Ana María Muñoz, Berta Loja, Jessica Michiko Miyasato, Jorge Antonio García, Roberto Andrés Cerro, Luis Abel Quiñones, Nelson Miguel Varela   +7 more
doaj   +1 more source

Comparison of CYP2C9 Activity in Ethiopian and Non-Ethiopian Jews Using Phenytoin as a Probe

Frontiers in Pharmacology, 2020
The pharmacokinetics of CYP2C9 substrates is characterized by substantial interethnic variability. The objective of the study was to compare CYP2C9 activity by using Phenytoin Metabolic Ratio (PMR) between Ethiopian and non-Ethiopian Jews.
Zahi Abu Ghosh, Shoshana Alamia, Chanan Shaul, Yoseph Caraco   +3 more
doaj   +1 more source

Association of CYP2C9*2 Allele with Sulphonylurea-Induced Hypoglycaemia in Type 2 Diabetes Mellitus Patients: A Pharmacogenetic Study in Pakistani Pashtun Population

Biomedicines, 2023
Polymorphism in cytochrome P450 (CYP) 2C9 enzyme is known to cause significant inter-individual differences in drug response and occurrence of adverse drug reactions.
Asif Jan, Muhammad Saeed, Ramzi A. Mothana, Tahir Muhammad, Naveed Rahman, Abdullah R. Alanzi, Rani Akbar   +6 more
doaj   +1 more source

CYP2C9 polymorphisms and CYP2C9*2 genotyping primers [PDF]

British Journal of Clinical Pharmacology, 2002
The primers first suggested by Wang et al.[1] for the genotyping of the CYP2C9 Arg144Cys mutation were based on the gene structure of CYP2C9 prior to knowledge of the gene structure of the closely related CYP2C19. Early studies cannot be faulted for using these primers, since the gene structure of CYP2C19 was not known.
openaire   +1 more source

Effect of CYP2C9 on the migration, invasion and proliferation of hepatocellular carcinoma cells [PDF]

Yixue xinzhi zazhi
Objective To explore whether CYP2C9 is involved in the occurrence and development of hepatocellular carcinoma (HCC) and its function in the migration, invasion and proliferation of HCC cells.Methods The transcriptome data of HCC were retrieved from the ...
ZHANG Tuo, LI Dajun, WANG Haitao, ZHANG Peng   +3 more
doaj   +1 more source

Evaluation of the Influence of CYP2C9* 2, CYP2C9*3 Gene Polymorphisms on the Efficacy and Safety of Postoperative Analgesia with Ketoprofen in Patients after Cardiac Surgery

Рациональная фармакотерапия в кардиологии, 2021
Aim. The aim of the study was to evaluate the efficacy and safety of ketoprofen as an analgesic therapy in patients with CYP2C9*2 (430C>T) rs179985 and CYP2C9*3 (1075A>C) rs1057910 gene polymorphisms after cardiac surgery.Material and methods.
T. E. Morozova, D. A. Shatsky, N. V. Shikh, E. V. Shikh, T. B. Andrushchyshina, M. V. Lukina, A. A. Kachanova, Zh. A. Sozaeva, G. N. Shuev, N. P. Denisenko, E. A. Grishina, D. A. Sychev   +11 more
doaj   +1 more source

CYP2C9 Polymorphism Study in Patients with Acute Back Pain and its Impact on the Effectiveness of Treatment with the Non-Steroidal Anti-Inflammatory Drugs

Львівський клінічний вісник, 2020
Introduction. Genetic factors can generate different variants of physiological responses to non-steroidal anti­inflammatory drugs (NSAIDs) – from the complete ineffectiveness of medicines to the appearance of adverse reactions.
Maslova I., Mykhailovska N., Slobodin T.
doaj   +1 more source

Functional Characterisation of Human CYP2C9 Allelic Variants in COS-7 cells

Frontiers in Pharmacology, 2016
Variability in activity of CYP2C9, which is involved in the metabolism of approximately 15% of current therapeutic drugs, is an important contributor to interindividual differences in drug response.
Huihui eDu, Zhiyun eWei, Yucai eYan, Yuyu eXiong, Xiaoqing eZhang, Lu eShen, Yunfeng eRuan, Xi eWu, Qingqing eXu, Lin eHe, Shengying eQin   +10 more
doaj   +1 more source

Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences

Human Genomics, 2023
Background Genetic variability in the cytochrome P450 CYP2C9 constitutes an important predictor for efficacy and safety of various commonly prescribed drugs, including coumarin anticoagulants, phenytoin and multiple non-steroidal anti-inflammatory drugs (
Yitian Zhou, Lenka Nevosadová, Erik Eliasson, Volker M. Lauschke   +3 more
doaj   +1 more source